RT Journal Article
SR Electronic
T1 CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP e867
OP e875
DO 10.1212/CPJ.0000000000001116
VO 11
IS 6
A1 Efthalia Angelopoulou
A1 Anastasia Bougea
A1 Andreas Papadopoulos
A1 Nikolaos Papagiannakis
A1 Athina-Maria Simitsi
A1 Christos Koros
A1 Marios K. Georgakis
A1 Leonidas Stefanis
YR 2021
UL http://cp.neurology.org/content/11/6/e867.abstract
AB Purpose of Review To evaluate whether CSF and circulating neurofilament light chain (NfL), a marker of axonal damage, could discriminate Parkinson disease (PD) from atypical parkinsonian syndromes (APSs).Recent Findings MEDLINE and Scopus were systematically searched, and 15 studies were included (1,035 patients with PD and 930 patients with APS). CSF NfL levels were 1.26 SDs higher in the APS group compared to the PD group (g = 1.26 [95% confidence interval 0.99–1.53]), and circulating NfL levels were 1.53 SDs higher in the APS group compared to the PD group (g = 1.53 [95% confidence interval 1.15–1.91]); 4 studies, 307 patients with PD, 197 patients with APS. Pooled areas under the curve were 0.941 (0.916–0.965) and 0.874 (0.802–0.946) for CSF and circulating NfL, corresponding to average sensitivities of 86% (79%–90%) and 91% (86%–95%), and specificity of 88% (82%–92%) and 76% (62%–85%), respectively.Summary These results strongly support the high diagnostic accuracy of both CSF and circulating NfL in differentiating PD from APS, highlighting their usefulness as promising biomarkers.